CN112225766A - Method for enriching and separating phenylethanoid glycosides compounds from cistanche deserticola extract - Google Patents
Method for enriching and separating phenylethanoid glycosides compounds from cistanche deserticola extract Download PDFInfo
- Publication number
- CN112225766A CN112225766A CN202011168586.4A CN202011168586A CN112225766A CN 112225766 A CN112225766 A CN 112225766A CN 202011168586 A CN202011168586 A CN 202011168586A CN 112225766 A CN112225766 A CN 112225766A
- Authority
- CN
- China
- Prior art keywords
- eluent
- ethanol
- polar solvent
- extract
- eluting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930182470 glycoside Natural products 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 40
- 239000000284 extract Substances 0.000 title claims abstract description 34
- -1 glycosides compounds Chemical class 0.000 title claims abstract description 33
- 241000336291 Cistanche deserticola Species 0.000 title claims abstract description 20
- 239000003480 eluent Substances 0.000 claims abstract description 109
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 claims abstract description 61
- 238000002360 preparation method Methods 0.000 claims abstract description 41
- 229930185474 acteoside Natural products 0.000 claims abstract description 32
- FBSKJMQYURKNSU-ZLSOWSIRSA-N acteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FBSKJMQYURKNSU-ZLSOWSIRSA-N 0.000 claims abstract description 32
- FBSKJMQYURKNSU-UKQWSTALSA-N acteoside I Natural products C[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O FBSKJMQYURKNSU-UKQWSTALSA-N 0.000 claims abstract description 32
- NJYVDFDTLLZVMG-UHFFFAOYSA-N echinacoside Natural products CC1OC(OC2C(O)C(OCCc3ccc(O)c(O)c3)OC(COC4OC(CO)C(O)C(O)C4O)C2OC(=O)C=Cc5cc(O)cc(O)c5)C(O)C(O)C1O NJYVDFDTLLZVMG-UHFFFAOYSA-N 0.000 claims abstract description 31
- FSBUXLDOLNLABB-ISAKITKMSA-N echinacoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FSBUXLDOLNLABB-ISAKITKMSA-N 0.000 claims abstract description 31
- FNMHEHXNBNCPCI-QEOJJFGVSA-N Isoacteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O[C@H](COC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@H]1O FNMHEHXNBNCPCI-QEOJJFGVSA-N 0.000 claims abstract description 29
- FNMHEHXNBNCPCI-RYEKTNFUSA-N isoacteoside Natural products C[C@@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](COC(=O)C=Cc3ccc(O)c(O)c3)O[C@@H](OCCc4ccc(O)c(O)c4)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O FNMHEHXNBNCPCI-RYEKTNFUSA-N 0.000 claims abstract description 29
- 239000011347 resin Substances 0.000 claims abstract description 17
- 229920005989 resin Polymers 0.000 claims abstract description 17
- 238000001179 sorption measurement Methods 0.000 claims abstract description 12
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 76
- 239000000287 crude extract Substances 0.000 claims description 37
- 239000002798 polar solvent Substances 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 238000001035 drying Methods 0.000 claims description 12
- 241000336316 Cistanche tubulosa Species 0.000 claims description 11
- 150000001298 alcohols Chemical class 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 239000003463 adsorbent Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 241000336315 Cistanche salsa Species 0.000 claims description 2
- 241000005787 Cistanche Species 0.000 description 21
- 239000000047 product Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 150000002338 glycosides Chemical class 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 7
- YDDMELPLARDERH-UHFFFAOYSA-N cistanoside Natural products CC1OC(OC2C(O)C(OCCc3ccc(O)c(OC(=O)C)c3)OC(COC4OC(CO)C(O)C(O)C4O)C2OC(=O)C=Cc5ccc(O)c(O)c5)C(O)C(O)C1O YDDMELPLARDERH-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- 241000308150 Orobanchaceae Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- ALERZNQPBWWLMW-UHFFFAOYSA-N 2''-acetylacteoside Natural products OC1C(O)C(O)C(C)OC1OC1C(OC(C)=O)C(OCCC=2C=C(O)C(O)=CC=2)OC(CO)C1OC(=O)C=CC1=CC=C(O)C(O)=C1 ALERZNQPBWWLMW-UHFFFAOYSA-N 0.000 description 2
- APXLKFCQWDJADY-VSALRCHLSA-N 2'-acetylacteoside Natural products C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](OC(=O)C)[C@H](O)[C@H]1O APXLKFCQWDJADY-VSALRCHLSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- KZLDMAIXPXOZCX-UHFFFAOYSA-N Tubuloside A Natural products OC1C(O)C(O)C(C)OC1OC1C(OC(C)=O)C(OCCC=2C=C(O)C(O)=CC=2)OC(COC2C(C(O)C(O)C(CO)O2)O)C1OC(=O)C=CC1=CC=C(O)C(O)=C1 KZLDMAIXPXOZCX-UHFFFAOYSA-N 0.000 description 2
- KJJKGAYHJMZKLA-DBDAIDROSA-N [(2r,3r,4s,5r,6r)-5-acetyloxy-6-[2-(3,4-dihydroxyphenyl)ethoxy]-2-(hydroxymethyl)-4-[[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]methoxy]oxan-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1CO[C@@H]1[C@@H](OC(C)=O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O[C@H](CO)[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 KJJKGAYHJMZKLA-DBDAIDROSA-N 0.000 description 2
- JXRBUKCEZLRNOI-BRJAJVCCSA-N [(2r,3r,4s,5r,6r)-5-acetyloxy-6-[2-(3,4-dihydroxyphenyl)ethoxy]-2-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-[[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]methoxy]oxan-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1CO[C@@H]1[C@@H](OC(C)=O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O[C@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 JXRBUKCEZLRNOI-BRJAJVCCSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YWJRHENUFPWISM-UHFFFAOYSA-N 3'-alpha-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1C(OC(=O)C=CC=2C=C(O)C(O)=CC=2)C(CO)OC(OCCC=2C=CC(O)=CC=2)C1O YWJRHENUFPWISM-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 229930189456 Campneoside Natural products 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- DORPKYRPJIIARM-UHFFFAOYSA-N Decaffeoylacteoside Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(OCCC=2C=C(O)C(O)=CC=2)OC(CO)C1O DORPKYRPJIIARM-UHFFFAOYSA-N 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- UBORTCNDUKBEOP-UHFFFAOYSA-N L-xanthosine Natural products OC1C(O)C(CO)OC1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UHFFFAOYSA-N 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241001299682 Salix purpurea Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- DORPKYRPJIIARM-GYAWPQPFSA-N Verbasoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O[C@H](CO)[C@H]1O DORPKYRPJIIARM-GYAWPQPFSA-N 0.000 description 1
- UBORTCNDUKBEOP-HAVMAKPUSA-N Xanthosine Natural products O[C@@H]1[C@H](O)[C@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-HAVMAKPUSA-N 0.000 description 1
- OWIYIDLFNMCIFO-HGTLEYCVSA-N [(2r,3r,4r,5r,6r)-6-[2-(3,4-dihydroxyphenyl)-2-methoxyethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O)OCC(OC)C=1C=C(O)C(O)=CC=1)C(=O)\C=C\C1=CC=C(O)C(O)=C1 OWIYIDLFNMCIFO-HGTLEYCVSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 1
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- UBORTCNDUKBEOP-UUOKFMHZSA-N xanthosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UUOKFMHZSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
Abstract
The invention relates to a method for enriching and separating phenylethanoid glycosides compounds from cistanche deserticola extract. Concentrating phenylethanoid glycosides compounds in the cistanche deserticola extract by using hydrophobic macroporous adsorption resin, eluting by using gradient polar eluent, separating the phenylethanoid glycosides compounds such as echinacoside, acteoside and isoacteoside to obtain high-purity echinacoside, acteoside and isoacteoside preparations, or combining the eluates to obtain the cistanche deserticola extract preparation with stable and controllable quality.
Description
Technical Field
The invention relates to an extraction process of traditional Chinese medicine Cistanche (Herba cistanches), in particular to a process method for enriching and separating phenylethanoid glycosides compounds from Cistanche extracts, which comprises the steps of enriching and separating phenylethanoid glycosides compounds such as echinacoside (echinacoside), acteoside (acteoside) and isoacteoside (isoacteoside) from the Cistanche extracts.
Background
The traditional Chinese medicine Cistanche (Herba Cistanches) is taken from the fleshy stem with scaly leaves of Cistanche genus plants in Orobanchaceae (Orobanchacae), is listed as the top grade in Shen nong Ben Cao Jing, is a traditional commonly used tonifying traditional Chinese medicine material, has the reputation of desert ginseng, has the efficacies of tonifying kidney yang, benefiting essence and blood, relaxing bowel and is mainly used for treating diseases such as male impotence, female infertility, soreness and weakness of waist and knees, myasthenia of bones and muscles, intestinal dryness and constipation and the like.
Cistanche tubulosa (cistanchee tubulosa) is a perennial parasitic herb of Cistanche, is mainly produced in dry areas such as deserts and deserts in northwest provinces of China, depends on absorption of nutrient vitamins of a host plant salix rubra, is also named as southern Xinjiang Cistanchis and salix rubifolia, and belongs to rare and precious medicinal materials. Cistanche tubulosa has been listed in the Chinese pharmacopoeia in 2005 for its effects of improving renal function, enhancing memory, regulating immune function, resisting senile dementia, resisting aging, resisting fatigue, etc.
From the beginning of the eighties of the last century, Japanese scholars began to systematically study the chemical components and pharmacological activities of cistanche plants, found that phenylethanoid glycosides are the main active ingredients of cistanche plants, have the effects of resisting oxidation, promoting substance metabolism, improving learning and memory, enhancing sexual function, and the like, and have conducted intensive studies on various phenylethanoid glycoside compounds (Sato T, et al, Yakugaku Zasshi, 1985, 105 (12): 1131), and there have been numerous reports on the efficacy studies of cistanche (Jimenez C, et al, nat Prod Rep, 1994, 11 (6): 591-606; Cometa F, et al, Fitotterapia, 1993, 64 (3): 195-217; Deng Min, et al, Germanocoe Sin,
2004, 25(10): 1276 and 1284), and Chinese pharmacopoeia 2010 also uses echinacoside (echinacoside) and acteoside (acteoside) in phenylethanoid glycosides as index components for evaluating the quality of Cistanchis herba.
Therefore, the development of a process for enriching and separating the phenylethanoid glycosides compounds from the cistanche has important significance for fully utilizing cistanche resources and controlling and improving the quality of extract preparations.
The macroporous resin separation and purification technology is widely applied to separating effective components of natural products at present, can be used for purifying compounds such as glycosides and flavonoids, has a different mode from a common chromatographic separation mode, is particularly suitable for being applied to industrial large-scale production processes, has the advantages of large adsorption capacity, simple regeneration, reliable effect and the like, and is one of the most beneficial methods in the field of separation and purification of natural products at present.
The inventor finally researches and separates phenylethanoid glycosides compounds from cistanche extracts through continuous effort tests, and utilizes hydrophobic macroporous adsorption resin to enrich the phenylethanoid glycosides compounds of the cistanche extracts, and then uses gradient polar eluent to elute, so as to separate key pharmacological active ingredients of cistanche such as echinacoside (echinacoside), acteoside (acteoside) and isoacteoside (isoacteoside). The eluates can be respectively dried to obtain high-purity echinacoside, acteoside and isoacteoside preparation; or directly mixing the eluates or mixing and drying after adjusting the proportion according to the requirement to obtain the cistanche deserticola extract preparation with stable and controllable quality.
Disclosure of Invention
The invention aims to provide a method for enriching and separating phenylethanoid glycosides compounds from cistanche deserticola extract. The method comprises the following steps:
(a) taking a crude extract prepared from cistanche deserticola, and enabling phenylethanoid glycosides compounds in the crude extract to be adsorbed on hydrophobic macroporous adsorption resin filled in an enrichment column through the enrichment column;
(b) eluting with a first eluent to obtain a first eluent containing echinacoside;
(c) eluting with a second eluent to obtain a second eluent containing acteoside; and
(d) eluting with a third eluent to obtain a third eluent containing isoacteoside;
wherein the polarity of the second eluent is less than or equal to the polarity of the first eluent, and the polarity of the third eluent is less than or equal to the polarity of the second eluent.
The method may further comprise after step (d):
(e) eluting with a fourth eluent to obtain a fourth eluent;
wherein the polarity of the fourth eluent is less than or equal to the third eluent.
The method may further comprise, prior to step (a):
(f) eluting with a fifth eluent to obtain a fifth eluent;
wherein the polarity of the fifth eluent is greater than or equal to the first eluent.
The crude extract is prepared by a method comprising the following steps:
(i) extracting fleshy stems of cistanche deserticola with a first polar solvent to obtain a primary extract;
(ii) passing the primary extract through a purification column, and adsorbing the phenylethanoid glycosides compounds in the primary extract to the purification column;
(iii) eluting with a second polar solvent to remove free impurities; and
(vi) eluting with a third polar solvent to obtain the crude extract containing the phenylethanoid glycosides compounds;
wherein the third polar solvent is less polar than the second polar solvent.
Another object of the present invention is to provide a preparation containing individual phenylethanoid glycosides compounds in high concentration and high purity: drying the first eluent to obtain a first preparation containing 70-90 wt% of echinacoside; drying the second eluent to obtain a second preparation containing 40-60 wt% of acteoside: drying the third eluent to obtain a third preparation containing 10-30 wt% of isoacteoside.
Another object of the present invention is to provide a cistanches Deserticolae extract preparation containing a high concentration of mixed phenylethanoid glycosides: and a fourth preparation prepared by combining and drying the first eluent, the second eluent and the third eluent comprises 20 to 75 weight percent of echinacoside, 3 to 55 weight percent of acteoside and 4 to 25 weight percent of isoacteoside.
Drawings
FIG. 1 is a UPLC chromatogram of a dried product of a crude extract of cistanche tubulosa as of example (1-2);
fig. 2a, 2b, 2c are UPLC chromatograms of the first, second, and third formulations in example 2.
Detailed Description
The invention is further illustrated by the following examples. It should be understood that the method described in the examples is only for illustrating the present invention and not for limiting the present invention, and that simple modifications of the preparation method of the present invention based on the concept of the present invention are within the scope of the claimed invention. All the starting materials and solvents used in the examples are commercially available products.
The use of a range of values (e.g., 5 to 100) in this specification should be understood to also include all rational numbers within the range as well as ranges consisting of any rational number within the range, and thus all possible combinations of values between the lowest value and the highest value recited are included in the range of values used in this specification. Further, as used herein, the terms "about", "about" or "approximately" substantially represent values within 20%, preferably within 10%, and more preferably within 5% of the recited values.
The invention provides a method for enriching and separating phenylethanoid glycosides compounds from cistanche deserticola extract. The method comprises the following steps:
(a) taking a crude extract prepared from cistanche deserticola, and enabling phenylethanoid glycosides compounds in the crude extract to be adsorbed on hydrophobic macroporous adsorption resin filled in an enrichment column through the enrichment column;
(b) eluting with a first eluent to obtain a first eluent containing echinacoside;
(c) eluting with a second eluent to obtain a second eluent containing acteoside; and
(d) eluting with a third eluent to obtain a third eluent containing isoacteoside.
Wherein the polarity of the second eluent is less than or equal to the polarity of the first eluent, and the polarity of the third eluent is less than or equal to the polarity of the second eluent.
The first, second, and third eluents are all polar solvents including, but not limited to, any of water, C1-C4 alcohols, and combinations of the foregoing; preferably, the first eluent is 30-35% of ethanol, the second eluent is 40-45% of ethanol, and the third eluent is 40-45% of ethanol; more preferably, the first eluent is 30% ethanol, the second eluent is 40% ethanol, and the third eluent is 40% ethanol.
The cistanche is not limited to a specific species of plants belonging to the genus cistanche of the family Orobanchaceae (Orobanchaceae), and preferably, the cistanche is cistanche tubulosa.
The hydrophobic macroporous adsorption resin is not limited to a specific kind, and preferably, the hydrophobic macroporous adsorption resin is AB-8 or D101.
In the step (a), the phenylethanoid glycosides compounds in the crude extract should be fully adsorbed on the hydrophobic macroporous adsorption resin; preferably, the flow rate of the crude extract passing through the enrichment column is 1.5-3L/h.
After step (d), in order to remove residual material on the hydrophobic macroporous adsorbent resin in order to reuse the enrichment column, the method further comprises after step (d):
(e) eluting with a fourth eluent to obtain a fourth eluent;
wherein the polarity of the fourth eluent is less than or equal to the third eluent.
The fourth eluent is a polar solvent including, but not limited to, any of water, C1-C4 alcohols, and combinations of the foregoing; preferably, the fourth eluent is 80-90% of ethanol; more preferably, the fourth eluent is 80% ethanol.
Before step (a), in order to remove polysaccharides and other substances on the hydrophobic macroporous adsorbent resin to increase the concentration and purity of the phenylethanoid glycosides in the first eluate, the second eluate and the third eluate, the method further comprises, before step (a):
(f) eluting with a fifth eluent to obtain a fifth eluent;
wherein the polarity of the fifth eluent is greater than or equal to the first eluent.
The fifth eluent is a polar solvent including, but not limited to, any one of water, C1-C4 alcohols, and combinations of the foregoing; preferably, the fifth eluent is 30% to 35% of ethanol, and more preferably, the fifth eluent is 30% of ethanol.
The method provided by the invention can be applied to any one of the crude extracts of cistanche salsa to enrich and separate the phenylethanoid glycosides compounds in the crude extract; preferably, the crude extract is a polar solvent extract of cistanche deserticola, the polar solvent is selected from any one of water, C1-C4 alcohols and combinations thereof.
The crude extract of cistanche deserticola is prepared, for example, by a method comprising the following steps:
(i) extracting fleshy stems of cistanche deserticola with a first polar solvent to obtain a primary extract;
(ii) passing the primary extract through a purification column, and adsorbing the phenylethanoid glycosides compounds in the primary extract to the purification column;
(iii) eluting with a second polar solvent to remove free impurities; and
(vi) eluting with a second polar solvent to obtain the crude extract containing phenylethanoid glycosides;
wherein the third polar solvent is less polar than the second polar solvent.
The first polar solvent, the second polar solvent, and the third polar solvent include, but are not limited to, any one of water, C1-C4 alcohols, and combinations of the foregoing. Preferably; the first polar solvent is water or a mixed solvent of water and ethanol, the second polar solvent is water, and the third polar solvent is a mixed solvent of water and ethanol.
The crude extract from step (vi) may be further concentrated or dried and redissolved and used in step (a).
By utilizing the method provided by the invention, the preparation containing the individual phenylethanoid glycosides compounds with high concentration and high purity can be obtained: drying the first eluate obtained in step (b) to obtain a first preparation containing 70-90 wt% echinacoside; drying the second eluate obtained in step (c) to obtain a second preparation comprising 40-60 wt% acteoside; drying the third eluate obtained in step (d) to obtain a third preparation containing 10 wt% -30 wt% of isoacteoside.
By utilizing the method provided by the invention, the cistanches Deserticola extract preparation containing the high-concentration mixed phenylethanoid glycosides compound can be obtained: and (3) combining the first eluent, the second eluent and the third eluent, and drying to obtain a fourth preparation containing 40-75 wt% of echinacoside, 10-55 wt% of acteoside and 5-25 wt% of isoacteoside.
The fourth preparation may further comprise at least one of 2 '-acetyl acteoside (2' -acetylacteoside), Bignonioside (campneoside) I, Bignonioside II, cistanoside (cistanuboside) A, cistanoside B1, cistanoside B2, cistanoside C1, cistanoside C2, xanthosine (crotoside), decaffeoylacteoside (decaffeoyloside), salidroside (rhodioside), syringoside A3 '-alpha-L-rhamnopyranoside (syringalide A3' -alpha-L-rhamnopyranoside), or tubuloside A (tubuloside A). Preferably, the fourth preparation contains not less than 70 wt% of phenylethanoid glycosides compounds.
The first eluent, the second eluent and the third eluent can be directly combined or combined after the proportion is adjusted according to the requirements of the preparation.
Many researches prove that the compounds containing phenylethanoid glycosides in cistanche deserticola have physiological/pharmacological effects with good effects, for example, echinacoside is helpful for neuroprotection and also has the effects of immunoregulation, blood sugar regulation and the like; isoacteoside can effectively inhibit amyloid protein (amyloid) accumulation, and has obvious effects on muscle protection and fatigue resistance. Furthermore, it has been mentioned in the previous patent literature (CN201210548516.0) of the applicant's research team that there is a range of ratios for which the efficacy is optimal in inhibiting the production, accumulation or aggregation of amyloid β peptide (amyloid β) using isoacteoside and acteoside compositions.
Therefore, the technology of enriching and separating the phenylethanoid glycosides compounds in the cistanche deserticola extract can not only improve the content of the phenylethanoid glycosides compounds in the product preparation, but also control the quality of the content and relative proportion of active ingredients in the preparation by adjusting the dosage proportion during the combination of the eluents, for example, the dosage of the first eluent is increased, so that the content of echinacoside in the fourth preparation can be improved, and a composition with better blood sugar regulation effect is provided; or adjusting the dosage of the first, second and third eluents to change the ratio of echinacoside, isoacteoside and acteoside in the fourth preparation to obtain a composition which is particularly effective in inhibiting amyloid beta peptide and can be used for preventing and delaying Alzheimer's disease.
Example 1: preparation of cistanche tubulosa crude extract and analysis of crude extract dried product
(1-1) preparation of crude extract of cistanche tubulosa
Taking 10 kg of succulent stem part of cistanche tubulosa, cutting into slices with the thickness of 0.4 cm, adding 8 times of water, soaking for 1 hour, heating and decocting for 2 hours, filtering, and collecting filtrate for later use. Adding 6 times of water into the residue, decocting for 1 hr, filtering, and collecting filtrate. The residue was extracted again 1 time in the manner described above. Mixing the filtrates, concentrating at 50 deg.C under reduced pressure to specific gravity of 1.10, adding ethanol to concentration of 60%, standing and refrigerating for 12 hr. Then the supernatant is poured out, and is decompressed and concentrated at 50 ℃ until no ethanol exists, thus obtaining the primary extract of the cistanche tubulosa.
And (3) loading the primary extract liquid on a pretreated AB-8 type macroporous adsorption resin (a purification column), and adsorbing the phenylethanoid glycoside compounds in the primary extract liquid onto the resin. Eluting with water with 8 times of the reserved volume of the column, and collecting the eluate for later use; eluting with 60% ethanol 8 times the column retention volume, and collecting eluate for use. Injecting the water eluent into the purification column again for adsorption, eluting with water with 6 times of the reserved volume of the column, and discarding the eluent; eluting with 60% ethanol 7 times the column retention volume, and collecting eluate for use. Mixing 2 times of 60% ethanol eluates, concentrating under reduced pressure at 50 deg.C, and recovering ethanol to obtain crude extract of Cistanchis herba.
The crude extract was spray dried to yield 1.2 kg of product.
(1-2) analysis of the crude extract dried product
Measuring the content of echinacoside, acteoside and isoacteoside in the crude extract dry product by Ultra Performance Liquid Chromatography (UPLC),
UPLC conditions: using a Waters acquisition BEH C18 chromatography column (1.7 μm, 2.1 × 100mm), column temperature: 35 ℃, mobile phase: acetonitrile/0.1% aqueous formic acid (14/86), flow rate: 0.35 mL/min, sample size: 1 μ L, detection wavelength: 333 nm.
USP echinacoside, acteoside and isoacteoside reference substances are accurately weighed, and are prepared into a solution containing 0.1mg of reference substance per 1mL by using 50% methanol to serve as a reference substance solution.
The sample solution is prepared by collecting the cistanche tubulosa extract 100mg obtained in (1-1), placing in a 50mL measuring flask, adding a proper amount of 50% methanol, treating with ultrasound to dissolve the extract, adding 50% methanol to dilute to 50mL, shaking, precisely measuring 1mL, placing in a 10mL measuring flask, adding 50% methanol to dilute to 10mL, and filtering with a 0.45 μm filter membrane to obtain the sample solution.
As shown in fig. 1, the content of echinacoside, acteoside 8.3 wt% and isoacteoside 3.2 wt% in the extract were determined by calculating peak areas of the respective index components in the control solution.
Example 2: enriching and separating phenylethanoid glycosides from the crude extract and analyzing the dried product
Taking the dry product of the crude extract of cistanche tubulosa obtained in step (1-1), redissolving with a proper amount of water to obtain a crude extract, loading the crude extract on a pretreated AB-8 type macroporous adsorption resin (enrichment column), and controlling the flow rate of the resin column to be 1.5L/h until the phenylethanoid glycosides in the crude extract are fully adsorbed on the resin.
Gradient elution is sequentially carried out on the enrichment column by 30% ethanol, 40% ethanol and 80% ethanol, and the components of the gradient elution are monitored by a polydiluted amine sheet (40% ethanol of a mobile phase, the detection wavelength is 333nm, and compared with standard products, echinacoside, acteoside and isoacteoside are used as reference products). Except that the 80% ethanol eluate was discarded, the gradient eluates were combined into a first eluate (eluted with 30% ethanol), a second eluate (eluted with 40% ethanol) and a third eluate (eluted with 40% ethanol) according to the detection results.
The first eluent, the second eluent and the third eluent are respectively dried, thus obtaining 460.8 g of the first preparation, 44.9 g of the second preparation and 29.6 g of the third preparation containing the phenylethanoid glycosides compounds.
The contents and components of the first, second and third preparations were analyzed by Ultra Performance Liquid Chromatography (UPLC). As the results of fig. 2a, 2b, 2c show, the first formulation contained 78.0 wt% echinacoside; the second preparation contains 57.4 wt% acteoside; the third preparation contains 28.5 wt% isoacteoside.
The first preparation, the second preparation and the third preparation are combined together, and the ratio of echinacoside to acteoside is 67.1 wt%, the ratio of acteoside to acteoside is 4.8 wt% and the ratio of isoacteoside to acteoside is 1.6 wt% in 535.3 g of dry products. Compared with the crude extract dry product, the concentration and purity of echinacoside are improved to nearly two times, and the concentrations of acteoside and isoacteoside are lower, so that the application of the echinacoside and the isoacteoside in the crude extract dry product can achieve the effect superior to that of the crude extract dry product when being applied to nerve protection, immune regulation, blood sugar regulation and the like.
The above examples show that the eluent and the dried preparation of the eluent after enrichment and separation of phenylethanoid glycosides by the method of the invention have higher concentration, high purity and high degree of freedom of phenylethanoid glycosides such as echinacoside, acteoside and isoacteoside, and have better application value when being added and manufactured into products such as food, medicine, cosmetics and the like.
Claims (15)
1. A method for enriching and separating phenylethanoid glycosides compounds from cistanche deserticola extract is characterized by comprising the following steps:
(a) taking a crude extract prepared from cistanche deserticola, and enabling phenylethanoid glycosides compounds in the crude extract to be adsorbed on hydrophobic macroporous adsorption resin filled in an enrichment column through the enrichment column;
(b) eluting with a first eluent to obtain a first eluent containing echinacoside;
(c) eluting with a second eluent to obtain a second eluent containing acteoside; and
(d) eluting with a third eluent to obtain a third eluent containing isoacteoside;
wherein the polarity of the second eluent is less than or equal to the polarity of the first eluent, and the polarity of the third eluent is less than or equal to the polarity of the second eluent.
2. The method of claim 1, wherein the hydrophobic macroporous adsorbent resin is AB-8 or D101.
3. The method of claim 1, wherein the flow rate of the crude extract through the enrichment column is 1.5 to 3L/h.
4. The method of claim 1, wherein the first eluent, the second eluent, the third eluent are each selected from any one of water, C1-C4 alcohols, and combinations of the foregoing; preferably, the first eluent is 30-35% of ethanol, the second eluent is 40-45% of ethanol, and the third eluent is 40-45% of ethanol; more preferably, the first eluent is 30% ethanol, the second eluent is 40% ethanol, and the third eluent is 40% ethanol.
5. The method according to claim 1, wherein the first formulation obtained by drying the first eluate comprises 70 wt% to 90 wt% echinacoside; drying the second eluent to obtain a second preparation containing 40-60 wt% of acteoside; and drying the third eluent to obtain a third preparation containing 10-30 wt% of isoacteoside.
6. The method of claim 1, wherein the first, second and third eluents are combined and dried to produce a fourth formulation comprising 20-75 wt% echinacoside, 3-55 wt% acteoside and 4-25 wt% isoacteoside; preferably, the fourth preparation comprises 40-75 wt% of echinacoside, 10-55 wt% of acteoside and 5-25 wt% of isoacteoside; more preferably, the fourth preparation contains not less than 70 wt% of phenylethanoid glycosides compounds.
7. The method of claim 1, further comprising after step (d):
(e) eluting with a fourth eluent to obtain a fourth eluent;
wherein the polarity of the fourth eluent is less than or equal to the third eluent.
8. The method of claim 7, wherein the fourth eluent is selected from any one of water, C1-C4 alcohols, and combinations of the foregoing; preferably, the fourth eluent is 80-90% of ethanol; more preferably, the fourth eluent is 80% ethanol.
9. The method of claim 1, wherein the method further comprises, prior to step (a):
(f) eluting with a fifth eluent to obtain a fifth eluent;
wherein the polarity of the fifth eluent is greater than or equal to the first eluent.
10. The method of claim 9, wherein the fifth eluent is selected from any one of water, C1-C4 alcohols, and combinations of the foregoing; preferably, the fifth eluent is 30-35% of ethanol; more preferably, the fifth eluent is 30% ethanol.
11. The method of claim 1, wherein the crude extract is a polar solvent extract of cistanche deserticola, the polar solvent being selected from any one of water, C1-C4 alcohols, and combinations of the foregoing.
12. The process of claim 1, wherein the crude extract is prepared by a process comprising:
(i) extracting fleshy stems of cistanche deserticola with a first polar solvent to obtain a primary extract;
(ii) passing the primary extract through a purification column, and adsorbing the phenylethanoid glycosides compounds in the primary extract to the purification column;
(iii) eluting with a second polar solvent to remove free impurities; and
(vi) eluting with a third polar solvent to obtain the crude extract containing the phenylethanoid glycosides compounds;
wherein the third polar solvent is less polar than the second polar solvent.
13. The method of claim 12, wherein the first polar solvent, the second polar solvent, and the third polar solvent are each selected from any one of water, C1-C4 alcohols, and combinations thereof; preferably, the first polar solvent is water or a mixed solvent of water and ethanol, the second polar solvent is water, and the third polar solvent is a mixed solvent of water and ethanol.
14. The process of claim 12, wherein said crude extract from step (vi) is further concentrated or dried for reconstitution.
15. The method of claim 1, wherein the cistanche salsa is cistanche tubulosa.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011168586.4A CN112225766A (en) | 2020-10-27 | 2020-10-27 | Method for enriching and separating phenylethanoid glycosides compounds from cistanche deserticola extract |
| CN202111256936.7A CN114478661A (en) | 2020-10-27 | 2021-10-27 | Method for enriching and separating phenylethanoid glycosides compounds from cistanche deserticola extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011168586.4A CN112225766A (en) | 2020-10-27 | 2020-10-27 | Method for enriching and separating phenylethanoid glycosides compounds from cistanche deserticola extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112225766A true CN112225766A (en) | 2021-01-15 |
Family
ID=74109066
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011168586.4A Pending CN112225766A (en) | 2020-10-27 | 2020-10-27 | Method for enriching and separating phenylethanoid glycosides compounds from cistanche deserticola extract |
| CN202111256936.7A Pending CN114478661A (en) | 2020-10-27 | 2021-10-27 | Method for enriching and separating phenylethanoid glycosides compounds from cistanche deserticola extract |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111256936.7A Pending CN114478661A (en) | 2020-10-27 | 2021-10-27 | Method for enriching and separating phenylethanoid glycosides compounds from cistanche deserticola extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN112225766A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114478661A (en) * | 2020-10-27 | 2022-05-13 | 杏辉天力（杭州）药业有限公司 | Method for enriching and separating phenylethanoid glycosides compounds from cistanche deserticola extract |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1268341C (en) * | 2003-03-04 | 2006-08-09 | 杏辉天力（杭州）药业有限公司 | Tubiflorous desert cistanche prepn containing phenethyl alcohol glycoside and its prepn process and use |
| JP6134331B2 (en) * | 2011-12-16 | 2017-05-24 | 杏輝天力（杭州）藥業有限公司 | Pharmaceutical composition for prevention or treatment of amyloid beta peptide-related diseases or symptoms |
| CN112225766A (en) * | 2020-10-27 | 2021-01-15 | 杏辉天力（杭州）药业有限公司 | Method for enriching and separating phenylethanoid glycosides compounds from cistanche deserticola extract |
-
2020
- 2020-10-27 CN CN202011168586.4A patent/CN112225766A/en active Pending
-
2021
- 2021-10-27 CN CN202111256936.7A patent/CN114478661A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114478661A (en) * | 2020-10-27 | 2022-05-13 | 杏辉天力（杭州）药业有限公司 | Method for enriching and separating phenylethanoid glycosides compounds from cistanche deserticola extract |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114478661A (en) | 2022-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102600268B1 (en) | Industrial use method of Stevia rebaudiana and its stevioside and chlorogenic acid | |
| CN101485705A (en) | Cooked Panax notoginseng and cooked Panax notoginseng standard extract and application thereof | |
| CN104857259B (en) | A kind of fritillaria flower extract and its preparation method and application | |
| CN106349324B (en) | The method of extraction separation crataegolic acid from olive growing leaves | |
| CN106242953A (en) | A kind of method preparing resveratrol from phoenix seed of Flos Moutan shell | |
| CN109879919B (en) | Method for separating and preparing three flavonoid glycosides from spina date seeds | |
| KR101052574B1 (en) | Method for preparing an extract fraction with enhanced ginsenosides Rg1 or Rb1 from ginseng | |
| CN114478661A (en) | Method for enriching and separating phenylethanoid glycosides compounds from cistanche deserticola extract | |
| CN108653338A (en) | Inhibit the active component production method and purposes of pathogenic entero becteria in nutgall | |
| CN100424092C (en) | Triterpene glucoside natural sweet taste inhibitor, its extraction method and application | |
| CN112870254A (en) | Method for separating flavone, saponin and polysaccharide from cyclocarya paliurus by continuous method | |
| CN109453234B (en) | Mulberry bark product and preparation method thereof | |
| CN108840892B (en) | Method for extracting quercetin and bergenin from Japanese ardisia | |
| CN106674312A (en) | Separation and purification method for high-purity monomer sweroside series components | |
| CN115010618B (en) | Separation and purification method of aureoyl amide alcohol ester capable of reducing uric acid and application thereof | |
| CN111304272A (en) | Method for preparing rare ginsenoside by converting panax notoginseng stem and leaf saponin through fusarium verticillii | |
| KR100570803B1 (en) | A process of extracting glabridine from licorice root | |
| CN107213180B (en) | Separation and extraction method of notoginseng flavone | |
| CN115634187A (en) | Dendrobium officinale flower extract, preparation method and application thereof, dendrobium officinale flower extract, application thereof, soothing cream and preparation method thereof | |
| CN109293726A (en) | Diol type ginsenoside extract and preparation method thereof | |
| CN102670935B (en) | Method for extracting total saponins from allium chinense | |
| CN111001189A (en) | Method for capturing and separating effective components in liquorice by using mixed-mode agarose gel medium | |
| CN106336440B (en) | The method of extraction separation oleanolic acid from olive growing leaves | |
| CN108997457B (en) | Method for extracting luteolin and quercetin-3-o-beta-glucopyranoside from populus tomentosa leaves | |
| KR20060098480A (en) | Formation of oil-soluble licorice extract including whitening bioactive materials |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210115 |